EGLN3
Prolyl hydroxylase EGLN3
As of the edition of 20 October 2026, EGLN3 (prolyl hydroxylase EGLN3, UniProt Q9H6Z9) has 2 drugs tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9H6Z9
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Blood and lymph; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Hormones; Nervous system; Bones, joints and muscles; Digestive system
- Registered trials of its drugs
- 105
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Roxadustat | Marketed | Phase 4 | none listed |
| Daprodustat | Marketed | Phase 4 | Ends 2038 |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 4 |
The other 2 companies at EGLN3
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at EGLN3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.